Pharmaceutical Technology

APRIL 12, 2023

FoundationOne CDx is a sequencing-based in vitro diagnostic device that can identify alterations in 324 genes from tumour samples. Individuals that develop lung cancer with no smoking history are genetically distinct from those who develop the cancer with a smoking history.

Genome 130

Genome Genomics In-Vitro Gene 130

XTalks

SEPTEMBER 30, 2020

The research shows that the activity of the immune messenger type 1 interferon (IFN) protein is diminished, either by genetic mutations or an autoimmune attack by neutralizing antibodies against it, in a subset of COVID-19 patients. Related: Low T Cell Counts Observed in COVID-19 Patients. Mutational Errors in COVID-19 Patients.

Antibody 135

Antibody Genetics Research In-Vitro 135

Bioengineer

JANUARY 16, 2024

Analysis of circulating tumor (ct) DNA at the time of treatment discontinuation or progression showed that 49% of patients in the AURA3 trial lacked the T790M mutation. Analysis of circulating tumor (ct) DNA at the time of treatment discontinuation or progression showed that 49% of patients in the AURA3 trial lacked the T790M mutation.

Genome 119

Genome Genomics Protein In-Vitro 119

Drug Discovery World

DECEMBER 13, 2022

Japanese researchers propose using RNA interference for correcting a mistake in the genetic code of patients with Fukuyama muscular dystrophy. . One form of FCMD is caused by a genetic abnormality in the ‘fukutin’ (FKTN) gene. One form of FCMD is caused by a genetic abnormality in the ‘fukutin’ (FKTN) gene.

RNA 52

RNA Genetics Gene In-Vitro 52

pharmaphorum

OCTOBER 29, 2020

The platform applies machine learning, human genetics, and functional genomics to generate predictive in vitro models that provide insights into disease progression. The private, San-Francisco based company focuses on DNA sequencing technology. Financial terms of the deal were not disclosed.

Development 45

Development DNA In-Vitro Genome 45

The Pharma Data

DECEMBER 22, 2020

This assay enables clinical geneticists to detect genetic aberrations associated with developmental delay, intellectual disabilities, congenital anomalies, and unexplained dysmorphic features. “We are truly excited and humbled to bring the power of diagnostic microarray testing to the Japanese market. About Agilent Technologies.

Genome 40

Genome Genomics Genetics In-Vitro 40

XTalks

NOVEMBER 7, 2022

Liquid biopsy tests in oncology involve isolating entities such as circulating tumor cells (CTC), circulating tumor DNA (ctDNA) and tumor-derived exosomes. These tumor-derived entities are used to derive genomic and proteomic data. The same webinar held a Q&A session with Dr. Bahassi and two other experts from Medpace, Dr. Lyon L.

Clinical Trials 98

Clinical Trials Clinical Trials Trials FDA Approval 98